AgomAb Therapeutics NV ( AGMB) has filed to raise $200 million in development capital in an IPO of its American Depositary Shares representing underlying common shares, according to SEC F-1/A ...
New review reveals how non-genomic estrogen signaling undermines treatment response and fuels tumor progression Hormone receptor–positive breast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results